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Abstract: Background  - Data on the presence of subclinical fibrosis across multiple organs in
patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating
through hepatic transient elastography (HTE) the prevalence and clinical impact of
subclinical liver fibrosis in a cohort of patients with IPF.
Methods  - Patients referred to the Centre for Rare Lung Disease of the University
Hospital of Modena (Italy) from March 2012 to February 2013with established
diagnosis of IPF and without a documented history of liver diseases were
consecutively enrolled and underwent HTE. Based on hepatic stiffness status as
assessed through METAVIR score patients were categorized as “  with liver fibrosis  ”
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(corresponding to a METAVIR score of F1-F4) and “  without liver fibrosis”   (METAVIR
F0).  Potential predictors of liver fibrosis were investigated through logistic regression
model among clinical and serological variables. The overall survival (OS) was
assessed according to liver fibrosis and multivariate Cox regression analysis was used
to identify independent predictors.
Results  - In 13 out of 37 patients (35%) with IPF a certain degree of liver fibrosis was
documented.No correlation was found between liver stiffness and clinical-functional
parameters. OS was lower in patients ‘  with liver fibrosis’  than in patients ‘  without
liver fibrosis’  (median months 33[23-55] vs. 63[26-94], p=0.038). Patients ‘  with liver
fibrosis’  presented a higher risk of death at seven years as compared to patients ‘
without liver fibrosis’  (HR=2.6, 95%CI[1.003–6.7],p= 0.049). Higher level of AST to
platelet ratio Index (APRI)was an independent predictor of survival (HR=4.52
95%CI[1.3–15.6], p=0.02).
Conclusions  - In our cohort, more than one third of IPF patients had concomitant
subclinical liver fibrosis that negatively affected OS. These preliminary claims further
investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its
clinical implication in patients with IPF.
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Abbreviations list 
BMI – Body Mass Index; TLC – Total Lung Capacity; FVC – Forced Vital Capacity; DLCO – Diffuse Lung 
Capacity for Carbon Dioxide; GAP – Gender, Age, P pulmonary function (FVC, DLCO); PBC - primary 
biliary cirrhosis; PSC - and primary sclerosing cholangitis; AMA - antimitochondrial antibody; ASMA 
- anti-smooth muscle antibodies; AST - aspartate aminotransferase; ALT - alanine 
aminostransferase;  γGT - gamma-glutamyl transpherase; IgG4 - immunoglobulin G4; APRI - AST to 
platelet ratio Index. 
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Abstract 
 
Background 
Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung 
fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography 
(HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF. 
Methods 
Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) 
from March 2012 to February 2013 with established diagnosis of IPF and without a documented 
history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness 
status as assessed through METAVIR score patients were categorized as “with liver fibrosis” 
(corresponding to a METAVIR score of F1-F4) and “without liver fibrosis” (METAVIR F0).  Potential 
predictors of liver fibrosis were investigated through logistic regression model among clinical and 
serological variables. The overall survival (OS) was assessed according to liver fibrosis and 
multivariate Cox regression analysis was used to identify independent predictors. 
Results 
In 13 out of 37 patients (35%) with IPF a certain degree of liver fibrosis was documented. No 
correlation was found between liver stiffness and clinical-functional parameters. OS was lower in 
patients ‘with liver fibrosis’ than in patients ‘without liver fibrosis’ (median months 33[23-55] vs. 
63[26-94], p=0.038). Patients ‘with liver fibrosis’ presented a higher risk of death at seven years as 
compared to patients ‘without liver fibrosis’ (HR=2.6, 95%CI[1.003–6.7],p= 0.049). Higher level of 
AST to platelet ratio Index (APRI) was an independent predictor of survival (HR=4.52 95%CI[1.3–
15.6], p=0.02). 
Conclusions 
In our cohort, more than one third of IPF patients had concomitant subclinical liver fibrosis that 
negatively affected OS. These preliminary claims further investigation aimed at clarifying the 
mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF. 
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Background 
Fibrogenesis is a key mechanism of tissue repair representing a physiological response to injury (1). 
In some pathological conditions, however, this pathway may result dysregulated so that undue 
fibroproliferation and extracellular matrix deposition occur, leading to tissue injury and dysfunction 
(2). Every tissue or organ may potentially be involved. While tissue specific injury has different 
origin, responses to injury and repair mechanisms are similar across different organs (3). Many 
distinct causes can contribute to the development of progressive fibrotic diseases, including genetic 
abnormalities, infections, exposure to toxins or pollutants, micro-aspiration of gastric content, 
tobacco smoke, chronic autoimmune inflammation (4). 
In idiopathic pulmonary fibrosis (IPF), a specific form of chronic and progressive interstitial 
pneumonia, repeated subclinical damages to alveolar epithelial cells (AECs) superimposed on 
accelerated epithelial aging lead to abnormal healing processes and deposition of interstitial fibrosis 
by fibroblasts and myofibroblasts (5,6). IPF represents a particularly arduous challenge, as, in 
contrast to other forms of lung injury, knowledge about the inciting injury, progressive 
fibroproliferation and lack of resolution are only partially understood (6-8). Consequently, there are 
no therapies able to halt or reverse the fibrotic process of IPF.  
Whether the activation of a fibrotic response in one organ might induce similar manifestations in 
other organs, as a result of the activation of common pathways, is unknown. Specifically, robust 
data about the co-existing presence of fibrotic disease across multiple organs in patients with IPF 
are lacking. With this background, the aim of our study is to evaluate the prevalence and clinical 
relevance of subclinical hepatic fibrosis through hepatic transient elastography (HTE) in patients 
diagnosed with IPF without clinically overt liver disease.  
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Materials and methods 
Study population 
We consecutively enrolled patients with established diagnosis of IPF referred to the Centre for Rare 
Lung Diseases of the University Hospital of Modena (Italy) over a 12-month period (from March 
2012 to February 2013). Demographic, clinical and functional data (forced vital capacity [FVC] and 
diffusing capacity of the lung for carbon monoxide [DLCO]) were recorded at the time of diagnosis. 
Each patient started antifibrotic treatment (either pirfenidone or nintedanib) at diagnosis. Disease 
severity score of IPF patients was recorded using the GAP-staging system, which includes gender, 
age, FVC and DLCO (9).  
The exclusion criteria were: documented history of chronic liver disease of known cause; positive 
screening for potential secondary causes of liver fibrosis including positive serology for chronic 
hepatitis B or C virus infection, history of alcohol abuse (> 2 units of alcohol), pharmacological 
treatments with prevalent hepatic metabolism, body mass index (BMI) > 29 kg/m2, inability to 
express a valid informed consent. 
The study was performed in accordance with the Declaration of Helsinki and was approved by the 
Ethics Committee of the University Hospital of Modena (Prot n. 2645). Informed consent was 
obtained for all study participants. 
Liver stiffness evaluation 
HTE was performed using Fibroscan® (EchosenseTM, Paris, France) at the Hereditary and Metabolic 
Center for Liver Diseases of the University Hospital of Modena. The exam was performed by internal 
medicine physicians experienced in hepatic fibrosis who were blinded to the past medical history of 
each patient and to the design of the study. HTE was performed with patient lying flat on the back, 
with the right arm tucked behind the head to facilitate the access to the hepatic right lobe. The tip 
of the probe transducer was placed on the skin between the rib bones at the level of the right 
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 7 
hepatic lobe. Once the measurement area had been located, signal acquisition was started. The 
Fibroscan® internal software (EchosenseTM, Paris, France) determined whether each measurement 
was successful or not. The overall liver stiffness corresponded to a mean of 10 successful 
measurements and was expressed in kiloPascals (kPa). Liver stiffness values ranged from 2.5 to 75 
kPa and were immediately available and operator-independent (10). Liver kPa stiffness threshold 
values were related to METAVIR parameters. In particular values range 0 - 5.2 kPa corresponded to 
METAVIR F0 (absence of fibrosis), range 5.3 kPa - 7.4 kPa to METAVIR F1 (fibrosis exist with 
expansion of portal zones – mild fibrosis), range 7.5 kPa-9 kPa to METAVIR F2 (fibrosis exist with 
expansion of most portal zones and occasional bridging – significant fibrosis), range 9.1 kPa - 13.1 
kPa to METAVIR F3 (fibrosis exist with expansion of most portal zones and marked bridging and 
occasional nodules – severe fibrosis), range 13.2 kPa - 75 kPa to METAVIR F4 (cirrhosis) respectively 
(11).  
Based on METAVIR parameters, IPF patients were categorized as ‘with liver fibrosis’ (if METAVIR 
value correspond to F1, F2, F3, F4) or ‘without liver fibrosis (if METAVIR value correspond to F0).  All 
patients enrolled in the study were further investigated for liver disease. These investigations 
included autoantibodies for the autoimmune hepatitis, primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) (anti-nuclear antibodies [ANA], anti-Liver and Kidney Microsomes [anti-
LKM] antibodies, antimitochondrial antibodies [AMA], anti-smooth muscle antibodies [ASMA]), 
serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl 
transferase (γGT), bilirubin, iron, and circulating immunoglobulins G4 (IgG4). The AST to platelet 
ratio Index (APRI), a predictor of liver fibrosis, was calculated as follows: AST/upper limit of normal 
x 100/platelet count (12,13).  
Statistical analysis 
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Categorical variables are expressed as absolute (n) and relative values (%) whereas continuous 
variables as median and interquartile range (IQR). To compare demographic data and baseline 
clinical characteristics between IPF patients ‘with liver fibrosis’ and IPF patients ‘without liver 
fibrosis’, Chi square test and Fisher’s exact test for categorical variables and Mann-Whitney U test 
for continuous variables were used, as appropriate.  
The correlation between liver stiffness values in kPa and each serum parameter was assessed for 
the entire study population and in the two groups of IPF patients (with liver fibrosis and without 
liver fibrosis) with the nonparametric Spearman’s rank method. Univariate logistic regression 
analysis was performed to detect predictors of liver fibrosis.  
The overall survival (OS) was calculated from diagnosis to death or lung transplantation, with data 
censured at September 1st, 2019. The cumulative survival rate was calculated using Kaplan-Meier 
method and the difference in the survival time between the two groups (‘with liver fibrosis’ and 
‘without liver fibrosis’) was assessed with log-rank test. A multivariate Cox regression analysis was 
used to determine which clinical and serological features were independently associated with 
survival. Only variables with a statistically significant and almost significant (0.05 < p < 0.09) 
association with OS at the univariate analysis were included in the multivariate model.  
All data were analysed using SPSS Software version 25.0 (New York, NY, US: IBM Corp. USA). P-
values < 0.05 were considered statistically significant. The statistical package GraphPad Prism 7.0 
(GraphPad Software, Inc. La Jolla, CA, USA) was used for graphs.  
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Results 
Forty-eight consecutive IPF patients were considered and 37 were finally enrolled in the study (Table 
1). In 29 patients (78%), HTE measurements for liver stiffness were considered reliable while for 8 
patients (22%) HTE measurements were unsuccessful as the software could not determine a final 
mean measurement of liver stiffness from ten valid measurements. Sixteen out of the 29 patients 
(55%) had a median liver stiffness value of 3.65 kPa (range, 2.60 - 5.10 kPa) corresponding to a 
METAVIR value of F0 and were classified as ‘without liver fibrosis’. Four patients had a median liver 
stiffness of 6.70 kPa (6.10 – 7.40 kPa) corresponding to a METAVIR value of F1, six patients had a 
median liver stiffness of 7.70 kPa (7.60 – 8.40 kPa) corresponding to a METAVIR value of F2, one 
patient had a liver stiffness value of 9.50 kPa corresponding to a METAVIR value of F3 and two 
patients had a liver stiffness value of 14.30 and 45.30 kPa corresponding to a METAVIR value of F4. 
Patients with liver stiffness corresponding to a METAVIR value of F1-F2-F3-F4 formed the group of 
IPF patients ‘with liver fibrosis’ (Figure 1).  Demographics and functional data of the 29 patients 
evaluated for liver stiffness are presented in Table 2. Patients ‘with liver fibrosis’ present lower age 
at diagnosis as compared to patients ‘without liver fibrosis’ (66 years [54-78] vs. 75 years [42-83] 
respectively; p = 0.04], but the two groups were similar with regard to the demographic features 
(sex, smoking history, radiological diagnosis) as well as functional parameters (FVC, DLCO, GAP 
score) (Figure 1). 
Serum analysis and correlations 
Blood tests (AST, ALT, γGT, platelets, total bilirubin, APRI index, IgG4, iron, ferritin and transferrin) 
were similar in patients ‘with liver fibrosis’ and ‘without liver fibrosis’ (Table 2). Notably, one of the 
two patients with F4 on HTE measurements had also high IgG4 levels (i.e. 419 mg/dL; normal values 
defined as lower than 86 mg/dL) and underwent liver biopsy, which revealed chronic idiopathic liver 
disease. No correlation between liver stiffness values (kPa) and clinical-functional parameters (age, 
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smoking history, FVC, DLCO, GAP score) or blood tests (AST, ALT, γGT, APRI index, IgG4, ferritin and 
transferrin) was found, neither in the entire study population of IPF patients evaluated for liver 
fibrosis nor when it was stratified by presence/absence of liver fibrosis. Gender, functional data at 
baseline, APRI test, and AST/ALT/ γGT were not associated with liver stiffness at univariate logistic 
regression (Table 3).  
Survival analysis 
Survival was estimates during a follow up time of 7 years, with median OS of 44 months. The OS of 
patients ‘with liver fibrosis’ was lower than patients ‘without liver fibrosis’, with a median OS of 33 
(23-55) months for patient ‘with liver fibrosis’ and 63 (26-94) months for patients ‘without liver 
fibrosis’(p=0.038) (Figure 2). Patients with liver fibrosis presented higher risk of death at seven years 
as compared to patients without hepatic involvement (HR 2.6, 95% CI 1.003 – 6.7; p= 0.049, Figure 
2) (Figure 3). 
Univariate analysis of factors associated with survival revealed that lower DLCO at diagnosis, GAP 
score III compared to GAP score I, presence of liver fibrosis and high levels of APRI score had a 
significant negative association with survival in the whole IPF population (Table 4). Multivariate 
analysis showed that only high level of APRI was an independent predictor of survival in our IPF 
cohort (HR: 4.52 95%CI [1.3 – 15.6]; p = 0.02). 
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Discussion 
Our study aimed at non-invasively assessing whether IPF patients without a clinical overt liver 
disease may present subclinical hepatic fibrosis. We found that IPF patients presented a significant 
prevalence of liver fibrosis (35%) that negatively affected survival. 
To our knowledge, robust evidences about the co-existing presence of fibrotic disease across 
multiple organs in patients with IPF are lacking. Collagen deposition is an indispensable and typically 
reversible part of wound healing, even though normal tissue repair can evolve into a progressive 
and irreversible fibrotic response when tissue injury is severe or if the wound-healing response 
results dysregulated (1,2,14). A feature shared by all fibrotic diseases is the activation and 
differentiation of fibroblasts into myofibroblasts, which are specialized contractile cells with higher 
profibrotic potential than fibroblasts. Within the fibroblastic foci, which define the histological usual 
interstitial pneumonia (UIP) pattern of lung fibrosis observed in IPF, myofibroblasts cause 
exaggerated extracellular matrix (ECM) deposit, that is the hallmark of the scarring process (14).  
Pathological liver fibrosis is similarly characterized by excessive accumulation of ECM proteins, 
(fibrillar collagens, glycoproteins and proteoglycans) and is induced by activated myofibroblasts 
(15). Bridging fibrosis and regeneration nodes are the clearest manifestation of this injury, being 
cirrhosis the end stage of this process (16). Excessive collagen deposition distorts the normal liver 
tissue architecture, leading to hepatocellular dysfunction and increased hepatic resistance to blood 
flow, which cause hepatic insufficiency and portal hypertension (17,18).  
Our data show that more than one third of IPF patients have a concomitant and clinically 
unremarkable fibrosing process in the liver. Having excluded subjects with potentially secondary 
causes for liver diseases, our IPF cohorts seems to be affected by an idiopathic/cryptogenic liver 
fibrosis. At baseline, IPF patients ‘with’ and ‘without liver fibrosis’ are homogeneous in terms of 
clinical and functional data as well as serological tests. Of interest, patients ‘with liver fibrosis’ gain 
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the diagnosis of IPF younger as compared to patients ‘without liver fibrosis’, maybe because the 
systemic involvement leads to an earlier onset of symptoms and disease awareness. Two examples 
of potential common pathways responsible for fibrotic processes occurring in different organs were 
proposed in the past: 1) Excessive telomere shortening, as a consequence of telomerase gene 
mutations, ultimately leading to apoptosis and organ failure, specifically in the lung, but also in the 
liver; 2) Germ-line mutations in telomerase components hTERT and hTR, that are found in a subset 
(8-15%) of patients with familial pulmonary fibrosis (19,20). Moreover, as compared with age-
matched controls, patients with IPF have shorter telomeres regardless of whether they carry 
telomerase-related mutations (21,22). In the liver, excessive telomere shortening, as a consequence 
of telomerase gene mutations, may impair the hepatocyte regenerative ability in response to 
chronic damage, thus facilitating fibrosis progression. 
Although percutaneous biopsy has traditionally been considered as the gold standard for the 
diagnosis and staging of chronic liver diseases, researchers have invested much efforts to develop 
noninvasive tests able to evaluate liver fibrosis. 
Both instrumental and serological methods to evaluate liver fibrosis were developed and validated 
(10,23-28). Among these, HTE has been evaluated as a non-invasive method for assessing liver 
fibrosis in a variety of chronic liver diseases while APRI is a simple index calculated with readily 
available laboratory results that proved to identify with a high degree of accuracy the presence of 
significant fibrosis and cirrhosis in patients with chronic HCV-related hepatitis (28). The mean liver 
stiffness value discovered in healthy patients without overt causes of liver disease and normal liver 
enzymes, has been estimated 5.5 ± 1.6 kPa. Age has no influence, but liver stiffness values have 
been found higher in obese patients and males (10). Liver stiffness assessment can be difficult in 
patients with BMI > 29 and in those with narrow intercostal space and cannot be performed in 
patients with ascites. According to experienced reported measurements, liver stiffness cannot be 
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measured in 5-15% of cases (24-27). In our study we have observed a greater proportion of 
unreliable measurements (22%) mainly due to either increased thickness of subcutaneous adipose 
tissue of the chest (n=6) or narrow intercostal spaces (n=2).   
Of great interest, our data showed that patients ‘with liver fibrosis’ have a shorter survival as 
compared to patients ‘without liver fibrosis’ (median survival of 33 vs. 63 months, respectively). The 
worst prognosis of patients with subclinical liver fibrosis opens an intriguing scenario, in the context 
of a disease, like IPF, universally considered as being limited to the lungs.  
These preliminary data may indicate the usefulness of a systemic approach to clarify the possible 
correlation between the fibrotic process across lung and liver. More focused studies are needed to 
identify cellular/molecular pathways of response to injury - if any - that are shared by liver and lung 
fibrosis. Detection of a subgroup of patients with idiopathic fibrotic disease involving more organs, 
would allow the definition of a new clinical phenotype, paving the way for future research. Future 
studies may also analyze whether short telomeres may contribute to such phenotype.  
If common pathogenetic mechanisms between lung and liver fibrosis are identified, this would 
inevitably impact on prognosis and treatment of IPF. Indeed, concomitant liver fibrosis may 
potentially influence response of IPF patients to antifibrotic drugs and may explain, at least in part, 
the variable degrees of functional decline and disease progression observed in both clinical trials 
and real-word studies of pirfenidone and nintedanib. Moreover, concomitant liver fibrosis may 
increase patient susceptibility to liver toxicity, which is one of the most common side effects of 
antifibrotic therapy. 
In our population, we finally analyzed which indicators could be independent predictors of survival. 
Our data revealed that only lower levels of APRI is an independent predictor of survival in IPF 
patients (HR: 4.52; 95%CI: 1.30 – 15.6; p = 0.02), which is added to the predictive role of liver fibrosis.  
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The findings of our study should be seen in light of some limitations. First of all, our study did not 
include an age-matched control group. Secondly the study population is relatively small; however, 
IPF is a rare disease, and collecting a large number of patients is challenging. Thirdly, patients with 
BMI > 29 (n=6) were excluded due to the intrinsic limitation of the HTE technique while 5 patients 
were excluded based on their morphotype. As a result, our findings need to be further confirmed 
before being generalizable to the broader population of IPF patients.  
In conclusion, our study shows that a relevant proportion of patients with IPF have also liver fibrosis; 
whether the co-existence of the two conditions is caused by common fibrogenic pathways needs to 
be explored further. In particular, this subset of IPF patients should be investigated for carriage of 
telomerase mutations and telomere length. IPF has long been considered the prototypic disease 
limited to the lung. However, if confirmed by larger studies, our data suggest that, at least in a subset 
of patients, IPF may be part of multiorgan fibrotic phenotype.   
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Figure legend 
 
Figure 1 
Parts of the whole population enrolled in the study. Grey box indicates patients with not reliable 
Fibroscan® measurements, light green box indicates patients without liver fibrosis and dark green 
box indicates patients with liver fibrosis.  
 
Figure 2 
Survival curves of IPF patients according to the presence of liver fibrosis.  
 
Figure 3 
Cumulative average survival time of IPF patients according to the presence of liver fibrosis.  
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Table 1 
 
Variable  
Patients – n (%) 37 (100) 
 Male – n (%) 26 (70) 
 Female – n (%) 11 (30) 
Age at diagnosis – years 71 (42–83) 
Smoking history – pack/years 10 (0-64) 
Clinical-radiological diagnosis – n (%) 28 (76) 
 Histological diagnosis – n (%) 9 (24) 
FVC at diagnosis – %pred. 78 (22–120) 
DLCO at diagnosis – %pred. 36 (11–102) 
 Gap score  
I 14 (38) 
II 16  (43) 
III 7 (19) 
 
Table 1 
Baseline characteristics of 37 IPF patients included in the study.  
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Table 2 
 
Variable Population 
evaluated for liver 
fibrosis 
(n =29) 
Without liver 
fibrosis  
(n = 16) 
With liver fibrosis 
 (n = 13) 
 
p Male – n (%) 
 
21 (72) 
 
10 (62) 
 
11 (85) 
 
0.23 
 Female – n (%) 8 (28) 6 (38) 2 (15)  
Age at diagnosis – 
years 
71 (42–83) 75 (42-83) 66 (54-78) 0.04 
Smoking history – 
pack/years 
10 (0-64) 3 (0-64) 21 (0-45) 0.42 
Radiological 
diagnosis – n (%) 
 
22 (76) 
 
13 (81) 
 
9 (69) 
 
0.66 
 Histological 
diagnosis – n (%) 
7 (24) 3 (19) 4 (31)  
FVC at diagnosis – 
%pred.  
78 (22–120) 72 (22-120) 79 (45-98) 0.34 
DLCO at diagnosis – 
%pred. 
 
35 (11–102) 
 
 
38 (11-65) 
 
 
35 (23-102) 
 
 
0.80 
 
 
GAP score 
 
    
I 
 
11 (38) 
 
5 (31) 
 
6 (46) 
 
 
 II 
 
14 (48) 
 
9 (56) 
 
5 (39) 
 
0.62 
 III 4 (14) 2 (13) 2 (15)  
Liver stiffness – kPa 
 
4.50 (2.60-45.30) 
 
3.65 (2.60-5.10) 
 
7.60 (6.10-45.30) 
 
< 0.0001 
 APRI index  
 
0.23 (0.16-1.24) 
 
0.25 (0.17-0.51) 
 
0.23 (0.16-1.24) 
 
0.78 
 Platelets – n x10
9/L 
 
250 (156-363) 
 
251 (157-363) 
 
236 (156-324) 
 
0.37 
 AST – U/L 
 
20 (13-82) 
 
20 (15-27) 
 
22 (13-82) 
 
0.86 
 ALT – U/L 
 
15 (8-80) 
 
14 (8-29) 
 
28 (8-80) 
 
0.10 
 γGT – U/L 
 
21 (12-643) 
 
20 (12-42) 
 
42 (12-643) 
 
0.14 
 Bilirubin total – 
umol/l 
 
0.43 (0.24-1.45) 
 
0.40 (0.26-0.65) 
 
0.51 (0.24-1.45) 
 
0.23 
 IgG 4 – mg/dL 
 
52 (10-618) 
 
52 (23-618) 
 
96 (10-433) 
 
0.88 
 Iron – umol/l 
 
91 (19-175) 
 
104 (86-139) 
 
78 (19-175) 
 
0.18 
 Ferritin – ug/l 
 
99 (22-276) 
 
92 (22-276) 
 
135 (59-227) 0.93 
 Transferrin – g/L 357 (258-522) 335 (258-399) 379 (275-522) 0.48 
 
 
Table 2 
Baseline characteristics of the 29 IPF patients evaluated for liver stiffness, of which 16 without liver fibrosis 
on HTE measurements and 13 with liver fibrosis. Data are presented as number and percentage for 
dichotomous values or median and ranges for continuous values.  
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Table 3  
  Univariate analysis 
  OR (95% CI) p Value 
Gender 
 
Female 
Male  
Ref. 
3.30 (0.60 - 26.26) 
 
0.19 
Age at diagnosis   0.95 (0.86 - 1.02) 0.17 
FVC at diagnosis - % pred. 
 
 
> 80 
60 – 80 
< 60 
Ref. 
0.14 (0.006 – 1.25) 
0.59 (0.10 – 3.08) 
 
0.11 
0.53 
DLCO at diagnosis - % pred. 
 
 
GAP score 
 
 
Platelets - n x109/L 
APRI index 
AST – U/L 
ALT – U/L 
γGT – U/L 
IgG 4 – mg/dL 
Iron – umol/l 
 
> 50 
35 -50 
< 35 
I 
II 
III 
 
 
Ref. 
0.66 (0.067 - 5.53) 
0.33 (0.03 - 2.8) 
Ref. 
1.2 (0.11 to 13.3) 
0.55 (0.01 – 1.08) 
0.99 (0.98 – 1.01) 
4.98 (0.12 - 874.1) 
1.05 (0.97 – 1.18) 
1.08 (1.01 - 1.19) 
0.04 (1.00 - 1.11) 
1.00 (0.99 – 1.00) 
0.98 (0.95 – 1.00) 
 
 
0.70 
0.31 
 
0.87 
0.60 
0.43 
0.42 
0.29 
0.06 
0.10 
0.63 
0.30 
 
    
 
Table 3 
Predictive factors of liver stiffness in the entire population of IPF patients evaluated for liver stiffness on 
Fibroscan® measurements. Values are expressed as HR (95%CI). Logistic regression analysis in relation to liver 
stiffness was used to determine the relationship of clinical, functional and serum levels of liver function with 
liver stiffness development.  
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Table 4 
 
 
 
Univariate analysis Multivariate analysis 
 HR (95% CI) p Value HR (95% CI)  p Value 
Gender 
 
female 
male 
-   - -     - 
1.08 (0.39 – 3.01)    0.87 -     - 
Age at diagnosis (years) < 71 - - - - 
  71 1.46 (0.57 – 3.73) 0.42 - - 
Smoking history (packyears) 
 
< 10      
 10                                 
- 
0.79 (0.25 – 2.46) 
- 
0.68 
- 
- 
- 
- 
FVC at diagnosis (%)  
 
 78 
< 78 
- 
1.40 (0.506 – 3.46) 
- 
0.46 
- 
- 
- 
- 
DLCO at diagnosis (%) 
 
 35 
< 35 
- 
3.95 (1.46 – 10.7) 
- 
0.007 
- 
3.18 (0.56 – 17.8) 
- 
0.18 
GAP score  
 
 
I 
II  
III 
- 
1.26 (0.45 – 3.54) 
5,40 (1.43 – 20.4) 
- 
0.66 
0.01 
- 
0.42 (0.07 – 2.49) 
3.91 (0.42 – 36.3) 
- 
0.33 
0.22 
METAVIR score  
 
F0 
F1-F2-F3-F4 
- 
2.60 (1.003 – 6.7) 
- 
0.04 
- 
1.39 (0.50-3.89) 
- 
0.51 
Platelets - n x109/L  
 
< 250 
 250 
- 
0.85 (0.30 – 2.42) 
- 
0.76 
- 
- 
- 
- 
APRI index 
 
< 0.23 
 0.23 
- 
2.39 (1.89 – 6.40) 
- 
0.01 
- 
4.52 (1.30-15.6) 
- 
0.02 
AST – U/L < 20 - - - - 
  20 1.54 (0.59 – 3.98) 0.37 - - 
ALT – U/L < 15 - - - - 
  15 1.58 (0.62 – 4.04) 0.33 - - 
γGT – U/L 
 
< 21 
 21 
- 
2.25 (0.82 – 6.15) 
- 
0.11 
- 
- 
- 
- 
Total bilirubin– umol/l < 0.43 - - - - 
  0.43 2.16 (0.72 – 6.47) 0.16 - - 
IgG 4 – mg/dL < 52 - - - - 
  52 0.83 (0.25 – 2.75) 0.76 - - 
Iron – umol/l < 91 - - - - 
  91 0.36 (0.10 – 1.34) 0.13 - - 
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Ferritin – ug/l < 99 - - - - 
  99 1.57 (0.14 – 17.7) 0.71 - - 
Transferrin – g/L 
 
< 357 
 357 
- 
1.46 (0.38 – 5.56) 
- 
0.57 
- 
- 
- 
- 
 
Table 4 
Predictors of overall survival in the population of IPF patients treated with antifibrotics. 
Values are expressed as HR (95%CI). Values are expressed as HR (95%CI). Univariate and multivariate Cox 
proportional hazard regression tests were used to determine the relationship of clinical, functional and 
serological characteristics with survival. 
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